Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3547917 | 0.87 | MIF (0.67) | MIFNPC1RAB9APKMKDM4E | |
| SCHEMBL2767357 | 0.83 | NPC1 (0.59) | MIFNPC1RAB9APKMKDM4E | |
| SCHEMBL2765598 | 0.83 | MIF (0.42) | MIFNPC1RAB9APKMKDM4E | |
| SCHEMBL3548006 | 0.83 | MIF (0.50) | MIFNPC1RAB9APKMKDM4E | |
| SCHEMBL3618891 | 0.82 | MIF (0.49) | MIFNPC1RAB9APKMALDH1A1 | |
| SCHEMBL3545651 | 0.82 | MIF (0.52) | MIFPKMALDH1A1GAAGRM2 | |
| SCHEMBL2766273 | 0.82 | STS (0.43) | MIF | |
| SCHEMBL3551114 | 0.82 | MIF (0.54) | MIFNPC1RAB9APKMKDM4E | |
| SCHEMBL2766991 | 0.82 | MIF (0.74) | MIFNPC1RAB9APKMKDM4E | |
| SCHEMBL2766407 | 0.81 | MIF (0.51) | MIFNPC1RAB9APKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795251-B2 | 3,4-dihydro-benzo[e][1,3]oxazin-2-ones | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| EP-1805170-B1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-7378416-B2 | MIF-inhibitors | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
| EP-1874742-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20070219189-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2007-09-20 | — | — | US | disclosed |
| EP-1805170-A1 | MIF-INHIBITORS | Novartis AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006108671-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006045505-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | CYP2C8, CYP2C18, CYP4B1 | MIF 2538/4885NPC1 341/4885RAB9A 3651/4885 |
| US-20070219189-A1 | MIF-INHIBITORS | MIF, FOXM1, CCR8 | MIF 1/4885NPC1 2226/4885RAB9A 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.